CA
NZ
UK
AU
IND
US
Willis Lease Finance Corporation filed a current report on August 6, 2026, disclosing that it entered into a Purchase and Sale Agreement on August 3, 2026, to acquire three commercial buildings in Coconut Creek, Florida for $118.0 million.
Cronos Group Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 6, 2026, covering the three and six months ended June 30, 2026.
Collegium Pharmaceutical, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the U.S. Securities and Exchange Commission, disclosing condensed consolidated balance sheet data and other financial information as of that date.
Novavax, Inc. filed its quarterly report on Form 10-Q with the SEC on August 6, 2026, covering the three and six months ended June 30, 2026, disclosing a net loss for both periods alongside a widened stockholders' deficit compared to year-end 2025.
ConocoPhillips filed its quarterly report on Form 10-Q with the SEC on August 6, 2026, covering the three- and six-month periods ended June 30, 2026, and reporting net income of $3,931 million for the second quarter.
Centrus Energy Corp. filed a current report on August 6, 2026, disclosing that it signed a contract with X-energy, LLC to supply low enriched uranium and high-assay low-enriched uranium for advanced reactors.
Climb Bio, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission for the period ended June 30, 2026, disclosing financial results, risk factors, and operational updates as a clinical-stage biopharmaceutical company.
Tanger Inc. and Tanger Properties Limited Partnership jointly filed their combined unaudited quarterly report for the period ended June 30, 2026, submitted to the SEC on August 6, 2026.
PaySign, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission for the period ended June 30, 2026, disclosing significant year-over-year increases in revenue, gross profit, and net income.
Compass Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on August 6, 2026, covering the period ended June 30, 2026, disclosing operating expenses, cash position, and balance sheet figures for the first half of the year.
Please wait processing your request...